Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

9.195 +0.445 (+5.09%)
Streaming Delayed Price Updated: 2:56 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
Via Chartmill
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
This Psychedelic Biotech Stock Is Soaring After Trump Executive Order ↗
COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the review process for... 
Via Benzinga
Topics Government
CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
What's going on in today's session ↗
Via Chartmill
News headline image
Why Compass Pathways Stock Rocketed 40% Today ↗
Compass Pathways may be the first to benefit from an accelerated approval process. 
Via The Motley Fool
Topics Government
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
The Psychedelic Revolution in Mental Healthcare ↗
Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and... 
Via The Motley Fool
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
Via MarketBeat
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗
The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter. 
Via Stocktwits
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Why Did Compass Pathways Stock Rocket Higher Today? ↗
Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval. 
Via The Motley Fool
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Compass (CMPS) Q2 Loss Improves 27% ↗
Via The Motley Fool
News headline image
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? ↗
Via The Motley Fool
News headline image
Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data ↗
The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart. 
Via Stocktwits
News headline image
What's going on in today's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Compass Pathways Stock Is Plunging Today: What's Going On? ↗
COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.